Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Impact of SaaS Platforms on Modern Healthcare Practices

Cloud-based software solutions are fundamentally reshaping how healthcare organizations deliver patient care and manage operations at scale

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Brian Urban · Brian UrbanFinthriveHealthcareHealthtrio
Share

Key takeaways

01

Cloud-based software solutions are fundamentally reshaping how healthcare organizations deliver patient care and manage operations at scale

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Software as a Service (SaaS) platforms are becoming increasingly pivotal in the digital transformation of the healthcare sector. These platforms, at the heart of modernizing patient care, are redefining the landscape with innovative solutions. Brian Urban, the Director of Innovation & Emerging Markets at FinThrive, stands at the forefront of this evolution. With a diverse background encompassing 14 years in health plan management, product innovation, and data analytics, Urban provides a comprehensive insight into the transformative power of SaaS in healthcare.

Delving into the specifics, Urban’s expertise allows him to dissect the role of SaaS platforms through three critical lenses: information exchange, social care technology, and virtual care models. He sheds light on how these components collectively revolutionize patient care, making healthcare more efficient and responsive.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

Brian Urban
Brian UrbanDirector of Innovation & Emerging Markets

Brian Urban has a deep skill set in health promotion and product development for rare disease and senior populations with Large Health Plans and Specialty Pharmacy. Urban has served as a speaker on such topics for the Alzheimer’s Association, Obediah Cole Prostate Cancer Foundation, Cigna Corp and Utica University Institute for the study of integrative healthcare. Urban has received a Masters of Science in Exercise Physiology-Health Promotion, Masters of Business Administration in Market Development and is currently completing a Masters in Public Health at Dartmouth College. Urban is currently a research-fellow sponsored by a Robert Wood Johnson Grant supporting Utica University public health research in Upstate New York.

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

Brian Urban
Brian Urban

Director of Innovation & Emerging Markets

Brian Urban has a deep skill set in health promotion and product development for rare disease and senior populations with Large Health Plans and Specialty Pharmacy. Urban has served as a speaker on such topics for the Alzheimer’s Association, Obediah Cole Prostate Cancer Foundation, Cigna Corp and Utica University Institute for the study of integrative healthcare. Urban has received a Masters of Science in Exercise Physiology-Health Promotion, Masters of Business Administration in Market Development and is currently completing a Masters in Public Health at Dartmouth College. Urban is currently a research-fellow sponsored by a Robert Wood Johnson Grant supporting Utica University public health research in Upstate New York.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512